ERBB2 and neoplasm: Since only a fraction of HER2+ breast cancer patients are responsive to the combination of anti-HER2 therapies and immune checkpoint inhibitors, a more comprehensive recognition of the composition of immune infiltration in the tumor microenvironment seems to be helpful in predicting treatment response and optimizing treatment strategy.